Midwest Chest Consultants — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$5,716	3
2024	Research	$32,356	9
2023	Research	$155,310	9
2022	Research	$117,494	2
2021	Research	$91,761	3
2020	Research	$46,108	11
2019	Research	$158,318	43

Breakdown

Who paid Research payments · program years 2019–2025

Amphastar Pharmaceuticals, Inc. $331,700 5 payments
Teva Pharmaceuticals USA, Inc. $187,989 27 payments
Cipla USA Inc. $61,684 31 payments
Chiesi USA, Inc. $25,691 17 payments

Studies the money was for Research payments · program years 2019–2025

Api-A007-Be-Pd $165,667 2 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $136,339 22 payments
Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmonary Disease (COPD) $101,898 1 payment
Pilot Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmonary Disease (COPD) $64,135 2 payments
U-Fs-Mu-As3120 $59,660 29 payments
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma $51,650 5 payments
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $12,961 6 payments
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $7,014 8 payments
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $5,716 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.